C. MOLINARO ET AL.* (MERCK, KIRKLAND, CANADA; MERCK, RAHWAY, USA AND ACTELION PHARMACEUTICALS, ALLSCHWIL, SWITZERLAND)

A Practical Synthesis of Renin Inhibitor MK-1597 (ACT-178882) via Catalytic Enantioselective Hydrogenation and Epimerization of Piperidine Intermediate


**Synthesis of Renin Inhibitor MK-1597**

**Significance:** The key feature in the synthesis of MK-1597 (ACT-178882) is the highly efficient ruthenium-catalyzed asymmetric hydrogenation of the tetrasubstituted alkene J followed by a mild epimerization reaction to set both stereogenic centers in H (trans/cis > 120:1).

**Comment:** The renin inhibitor MK-1597 is a promising lead in the treatment of hypertension. It was synthesized in nine steps (longest linear sequence) in 29% overall yield. Most of the intermediates were solids, but they were not purified before being used in the succeeding steps.